GLP-1 Receptor Agonist [EPC]

176236 reported adverse events

Drugs of this class: SEMAGLUTIDE LIRAGLUTIDE DULAGLUTIDE EXENATIDE (INSULIN DEGLUDEC AND LIRAGLUTIDE) INSULIN GLARGINE AND LIXISENATIDE LIXISENATIDE ORAL SEMAGLUTIDE

These side effects are most commonly reported by patients taking drugs of the GLP-1 Receptor Agonist [EPC] class:

# Side effect Count
0 BLOOD GLUCOSE INCREASED 28270
1 NAUSEA 27959
2 WEIGHT DECREASED 18724
3 INJECTION SITE PAIN 12203
4 VOMITING 11958
5 DECREASED APPETITE 10729
6 DIARRHOEA 10614
7 BLOOD GLUCOSE DECREASED 8552
8 INJECTION SITE HAEMORRHAGE 8268
9 PANCREATITIS 5983
See all common reactions for GLP-1 Receptor Agonist [EPC]

Drugs of the GLP-1 Receptor Agonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EARLY SATIETY 682 0.4938
1 MEDULLARY THYROID CANCER 74 0.4044
2 INJECTION SITE NODULE 2993 0.3524
3 DRUG DELIVERY SYSTEM ISSUE 248 0.3503
4 INTENTIONAL DEVICE MISUSE 1164 0.3238
5 GLYCOSYLATED HAEMOGLOBIN ABNORMAL 135 0.3214
6 ACCIDENTAL UNDERDOSE 1506 0.3018
7 INJECTION SITE EXTRAVASATION 2808 0.2674
8 GLYCOSYLATED HAEMOGLOBIN DECREASED 247 0.2673
9 PANCREATIC CARCINOMA METASTATIC 582 0.2538
See all enriched reactions for GLP-1 Receptor Agonist [EPC]